| Literature DB >> 32259785 |
Mary B Daly1, Robert Pilarski2, Matthew B Yurgelun3, Michael P Berry4, Saundra S Buys5, Patricia Dickson6, Susan M Domchek7, Ahmed Elkhanany8, Susan Friedman9, Judy E Garber3, Michael Goggins10, Mollie L Hutton11, Seema Khan12, Catherine Klein13, Wendy Kohlmann5, Allison W Kurian14, Christine Laronga15, Jennifer K Litton16, Julie S Mak17, Carolyn S Menendez18, Sofia D Merajver19, Barbara S Norquist20, Kenneth Offit21, Tuya Pal22, Holly J Pederson23, Gwen Reiser24, Kristen Mahoney Shannon25, Kala Visvanathan10, Jeffrey N Weitzel26, Myra J Wick27, Kari B Wisinski28, Mary A Dwyer29, Susan D Darlow29.
Abstract
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic provide recommendations for genetic testing and counseling for hereditary cancer syndromes, and risk management recommendations for patients who are diagnosed with syndromes associated with an increased risk of these cancers. The NCCN panel meets at least annually to review comments, examine relevant new data, and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32259785 DOI： 10.6004/jnccn.2020.0017
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908